FATE (STOCKS)
Fate Therapeutics, Inc.
$2.010000
-0.050000 (-2.43%)
Prev close: $2.060000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Bahram Valamehr
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $235.45M
- Employees
- 181
- P/E (TTM)
- -1.89
- P/B (TTM)
- 1.33
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $6.32M |
| Benefits Costs and Expenses | -$76.71M |
| Costs And Expenses | $153.00M |
| Operating Expenses | $145.74M |
| Research and Development | $103.40M |
| Other Operating Expenses | $42.34M |
| Operating Income/Loss | -$139.42M |
| Income/Loss From Continuing Operations After Tax | -$129.91M |
| Income/Loss From Continuing Operations Before Tax | $47.05M |
| Net Income/Loss | -$129.91M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$129.91M |
| Net Income/Loss Available To Common Stockholders, Basic | -$129.91M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.09 |
| Diluted Earnings Per Share | -$1.09 |
| Basic Average Shares | 357,710,976 |
| Diluted Average Shares | 357,710,976 |
| Assets | $284.92M |
| Current Assets | $179.53M |
| Cash | $174.80M |
| Other Current Assets | $4.73M |
| Noncurrent Assets | $105.39M |
| Fixed Assets | $54.26M |
| Other Non-current Assets | $51.13M |
| Liabilities | $105.21M |
| Current Liabilities | $30.69M |
| Accounts Payable | $3.28M |
| Other Current Liabilities | $27.41M |
| Noncurrent Liabilities | $74.52M |
| Equity | $179.71M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $179.71M |
| Liabilities And Equity | $284.92M |
| Net Cash Flow From Operating Activities | -$103.10M |
| Net Cash Flow From Operating Activities, Continuing | -$103.08M |
| Net Cash Flow From Investing Activities | $92.08M |
| Net Cash Flow From Investing Activities, Continuing | $92.08M |
| Net Cash Flow From Financing Activities | $21.59M |
| Net Cash Flow From Financing Activities, Continuing | $21.57M |
| Net Cash Flow | $10.57M |
| Net Cash Flow, Continuing | $10.57M |
| Comprehensive Income/Loss | -$130.18M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$130.05M |
| Other Comprehensive Income/Loss | -$32.39M |